254 related articles for article (PubMed ID: 20196171)
21. Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
He X; Pang Z; Zhang X; Lan T; Chen H; Chen M; Yang H; Huang J; Chen Y; Zhang Z; Jing W; Peng R; Zhang H
Am J Surg Pathol; 2018 Sep; 42(9):1143-1155. PubMed ID: 30001240
[TBL] [Abstract][Full Text] [Related]
22. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
Pilotti S; Della Torre G; Lavarino C; Sozzi G; Minoletti F; Vergani B; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
[TBL] [Abstract][Full Text] [Related]
23. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
24. COPS3 amplification and clinical outcome in osteosarcoma.
Yan T; Wunder JS; Gokgoz N; Gill M; Eskandarian S; Parkes RK; Bull SB; Bell RS; Andrulis IL
Cancer; 2007 May; 109(9):1870-6. PubMed ID: 17366602
[TBL] [Abstract][Full Text] [Related]
25. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2.
Reifenberger G; Reifenberger J; Ichimura K; Meltzer PS; Collins VP
Cancer Res; 1994 Aug; 54(16):4299-303. PubMed ID: 8044775
[TBL] [Abstract][Full Text] [Related]
26. Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma.
Ragazzini P; Gamberi G; Benassi MS; Orlando C; Sestini R; Ferrari C; Molendini L; Sollazzo MR; Merli M; Magagnoli G; Bertoni F; Bohling T; Pazzagli M; Picci P
Cancer Detect Prev; 1999; 23(2):129-36. PubMed ID: 10101594
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and MDM2 immunohistochemistry as a diagnostic adjunct.
Jeon DG; Koh JS; Cho WH; Song WS; Kong CB; Cho SH; Lee SY; Lee SY
J Orthop Sci; 2015 May; 20(3):529-37. PubMed ID: 25740728
[TBL] [Abstract][Full Text] [Related]
28. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases.
Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ
Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098
[TBL] [Abstract][Full Text] [Related]
29. Comparative genomic hybridization of low-grade central osteosarcoma.
Tarkkanen M; Böhling T; Gamberi G; Ragazzini P; Benassi MS; Kivioja A; Kallio P; Elomaa I; Picci P; Knuutila S
Mod Pathol; 1998 May; 11(5):421-6. PubMed ID: 9619593
[TBL] [Abstract][Full Text] [Related]
30. Parosteal osteosarcoma.
Hang JF; Chen PC
Arch Pathol Lab Med; 2014 May; 138(5):694-9. PubMed ID: 24786129
[TBL] [Abstract][Full Text] [Related]
31. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
[TBL] [Abstract][Full Text] [Related]
32. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
[TBL] [Abstract][Full Text] [Related]
33. MDM2/CDK4 gene amplification in large/deep-seated 'lipomas': incidence, predictors and clinical significance.
Wong DD; Low IC; Peverall J; Robbins PD; Spagnolo DV; Nairn R; Carey-Smith RL; Wood D
Pathology; 2016 Apr; 48(3):203-9. PubMed ID: 27020493
[TBL] [Abstract][Full Text] [Related]
34. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
[TBL] [Abstract][Full Text] [Related]
35. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
Khatib ZA; Matsushime H; Valentine M; Shapiro DN; Sherr CJ; Look AT
Cancer Res; 1993 Nov; 53(22):5535-41. PubMed ID: 8221695
[TBL] [Abstract][Full Text] [Related]
36. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer.
Wikman H; Nymark P; Väyrynen A; Jarmalaite S; Kallioniemi A; Salmenkivi K; Vainio-Siukola K; Husgafvel-Pursiainen K; Knuutila S; Wolf M; Anttila S
Genes Chromosomes Cancer; 2005 Feb; 42(2):193-9. PubMed ID: 15543620
[TBL] [Abstract][Full Text] [Related]
37. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.
Ragazzini P; Gamberi G; Pazzaglia L; Serra M; Magagnoli G; Ponticelli F; Ferrari C; Ghinelli C; Alberghini M; Bertoni F; Picci P; Benassi MS
Histol Histopathol; 2004 Apr; 19(2):401-11. PubMed ID: 15024701
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
[TBL] [Abstract][Full Text] [Related]
39. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
[TBL] [Abstract][Full Text] [Related]
40. [Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma].
Li L; Zhang M; Dong RF; Su YB; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):237-242. PubMed ID: 38433050
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
